Victory Capital Management
ACRS icon

Victory Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Victory Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.3K Buy
12,718
+969
+8% +$4.32K ﹤0.01% 2367
2026
Q1 		$44.1K Buy
11,749
+1,098
+10% +$3.71K ﹤0.01% 2321
2025
Q4 		$32.1K Buy
10,651
+23
+0.2% +$58 ﹤0.01% 2361
2025
Q3 		$20.2K Sell
10,628
-376
-3% -$656 ﹤0.01% 2398
2025
Q2 		$15.6K Sell
11,004
-5
-0% -$7 ﹤0.01% 2456
2025
Q1 		$16.8K Buy
+11,009
New +$23.5K ﹤0.01% 2436
2022
Q1 		– Sell
-22,650
Closed -$329K – 2724
2021
Q4 		$329K Sell
22,650
-11,456
-34% -$174K ﹤0.01% 2350
2021
Q3 		$614K Buy
34,106
+16,282
+91% +$261K ﹤0.01% 2070
2021
Q2 		$313K Buy
17,824
+9,746
+121% +$221K ﹤0.01% 2398
2021
Q1 		$204K Buy
+8,078
New +$158K ﹤0.01% 2520
2020
Q2 		– Sell
-6,331
Closed -$7K – 2508
2020
Q1 		$7K Buy
+6,331
New +$8.62K ﹤0.01% 3190
2019
Q4 		– Sell
-6,910
Closed -$7K – 2633
2019
Q3 		$7K Buy
+6,910
New +$9.8K ﹤0.01% 3360
2019
Q2 		– Sell
-102,251
Closed -$612K – 1822
2019
Q1 		$612K Buy
102,251
+29,970
+41% +$199K ﹤0.01% 1303
2018
Q4 		$534K Sell
72,281
-1,350
-2% -$13.9K ﹤0.01% 1346
2018
Q3 		$1.07M Sell
73,631
-3,740
-5% -$64.1K ﹤0.01% 1262
2018
Q2 		$1.54M Sell
77,371
-4,120
-5% -$76.1K ﹤0.01% 1134
2018
Q1 		$1.43M Buy
81,491
+7,990
+11% +$169K ﹤0.01% 1159
2017
Q4 		$1.81M Buy
73,501
+14,290
+24% +$348K ﹤0.01% 1069
2017
Q3 		$1.53M Buy
59,211
+18,190
+44% +$488K ﹤0.01% 1095
2017
Q2 		$1.11M Sell
41,021
-440
-1% -$12K ﹤0.01% 1155
2017
Q1 		$1.24M Sell
41,461
-14,699
-26% -$424K ﹤0.01% 1090
2016
Q4 		$1.52M Buy
+56,160
New +$1.43M ﹤0.01% 980

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Victory Capital Management's ACRS Position: Q2 2026 in Review

Victory Capital Management increased its Aclaris Therapeutics (ACRS) stake by 8.2% in Q2 2026, buying an estimated $4.32K and bringing the position to 12,718 shares worth $67.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2367.

Victory Capital Management first reported a position in ACRS in Q4 2016 and has held it in 22 quarters since. The position peaked at $1.81M in Q4 2017. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Victory Capital Management held 12,718 shares of Aclaris Therapeutics worth $67.3K as of Q2 2026.
  • Victory Capital Management bought 969 Aclaris Therapeutics shares in Q2 2026, an estimated $4.32K.
  • Aclaris Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2367 holding.
  • Victory Capital Management first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 22 quarters since.
  • Victory Capital Management's Aclaris Therapeutics position peaked at $1.81M in Q4 2017.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.